Barclays PLC Arcutis Biotherapeutics, Inc. Call Options Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
Call Options
1 transactions
Others Institutions Holding ARQT
# of Institutions
218Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$203 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$188 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$181 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$145 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$142 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $991M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...